<?xml version="1.0" encoding="UTF-8"?>
<p>Despite multiple advantages of treating early, almost all ongoing trials are focused on hospitalized patients. At this later stage of COVID-19, although viral replication may augment disease progression, cytokine storm is an increasingly relevant aspect of pathogenesis, which is reflected by the use of biologics in the critically ill [
 <xref rid="CIT0022" ref-type="bibr">22</xref>], and incomplete efficacy of antiviral agents [
 <xref rid="CIT0023" ref-type="bibr">23</xref>]. A rational therapeutic approach would prevent critical illness altogether.
</p>
